Healthcare / BiotechnologyNasdaqGS
$9.00
+0.31 (+3.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-191.1M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$743M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.5%
↓Gross Margin
N/A
•Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-247.3M · FCF $-198.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Net Income | $-247.3M | $-247.3M | $-215.8M | $-174.3M | $-118.0M | $-80.9M | $-52.6M | $-30.8M | $-19.7M | $-7.7M |
| EBITDA | $-235.4M | $-235.4M | $-206.1M | $-167.4M | $-113.7M | $-78.2M | $-55.7M | $-30.8M | $-19.1M | $-9.5M |
| EPS | -3.07 | -3.07 | -3.24 | -2.99 | -2.26 | -1.75 | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.18 | 0.18 | 0.20 | 0.11 | 0.08 | — | 0.05 | — | — | — |
| Current Ratio | 5.60 | 5.60 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-198.9M | $-198.9M | $-191.1M | $-130.3M | $-84.5M | $-63.8M | $-67.1M | $-28.0M | $-16.1M | $-7.3M |
| Returns | ||||||||||
| ROE | -59.5% | -59.5% | -57.6% | -31.4% | -28.7% | -16.2% | -28.6% | -22.4% | 70.2% | 66.9% |
| Valuation | ||||||||||
| P/B | 1.74 | 1.74 | 1.31 | 1.75 | 2.32 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| EPS Growth | 5.2% | 5.2% | -8.4% | -32.3% | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.24 → -3.07
Residual
+0.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.